HALO · NASDAQ · STOCK
Halozyme (HALO) Stock Analysis
$110.41
52W $61.23 – $116.85
51/100
$13.10B
31.4
0.88
Is HALO Bullish or Bearish?
Mixed.
Innellis AI committee rates Halozyme (HALO) Watch with a composite score of 51/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +8.73 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -11.27 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — high leverage (debt-to-equity 43.89) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 180.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 41.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 30.1 is moderate-to-rich — Value
- Price-to-book of 162.1x prices in significant intangible value — Value
- Debt-to-equity of 43.89 adds balance-sheet risk to the value case — Value
- EPS declining -23.5% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
51/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 90%
of 192 Healthcare peers
Value Analyst
neutral
45
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 180.6% shows genuine earnings power backing the valuation
− P/E of 30.1 is moderate-to-rich
Growth Analyst
neutral
47
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Revenue growing 41.1% YoY -- genuine top-line momentum
− EPS declining -23.5% YoY despite any revenue growth
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 43.89) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 51.3 to 51.3.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
51.0
Neutral
MACD Histogram
-0.682
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.47
Inside Bands
Price vs Moving Averages
EMA 9
$110.21
Above
EMA 21
$109.70
Above
EMA 50
$103.92
Above
EMA 200
$84.22
Above
Fundamental Analysis
Valuation
45
Growth
41
Profitability
100
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
31.4×
P/B Ratio
90.21×
PEG Ratio
-1.46
Dividend Yield
0.00%
52W High
$116.85
52W Low
$61.23
Quality & Growth
ROE
—
ROA
1254.9%
Gross Margin
8242.4%
Operating Margin
5594.6%
Revenue Growth YoY
—
Debt / Equity
14.95
AI Fundamental Assessment
P/E ratio of 31.4 (rich relative to a 15-40x range); Price-to-book of 90.2x; PEG ratio of -1.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 649.2%; Return on assets of 12.5%; Net margin of 24.9%; Gross margin of 82.4%; Current ratio of 2.71 (healthy short-term liquidity); Debt-to-equity of 14.95; Free cash flow per share is positive (6.87); Most recent quarter beat estimates by 21.7%; 2 consecutive earnings beats; EPS growth decelerating (+766.7% -> +42.5% QoQ); Average YoY EPS growth of 48.0%; Analyst estimates falling over recent quarters
Get the Full HALO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →